摘要
肝细胞癌是我国第三大癌症死因。近年来,靶向和免疫治疗的应用使得肝癌患者生存率得到提高。但受限于肿瘤异质性及疗效预测生物标志物的缺乏,肝细胞癌患者对治疗应答存在显著差异,而以蛋白基因组为核心的多组学研究以及高通量药物筛选平台的发展,将有助于开发肝细胞癌新型临床治疗策略和精准用药疗效预测,从而逐步实现个体化的精准诊疗。
Hepatocellular carcinoma(HCC)is the third leading cause of cancer mortality in China.In recent years,the application of targeted therapy and immunotherapy has improved the survival rate of HCC patients.However,a significant difference in treatment response is observed among HCC patients due to tumor heterogeneity and a lack of biomarkers to predict efficacy.The advance in proteogenomics-centered multi-omics studies and the development of high-throughput drug screening platforms will help to develop new clinical treatment strategies for HCC and new methods for predicting the efficacy of precision medication,thereby realizing personalized precision diagnosis and treatment.
作者
董良庆
高强
DONG Liangqing;GAO Qiang(Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2022年第3期510-514,共5页
Journal of Clinical Hepatology
基金
国家自然科学基金(81961128025,82002514)
上海市优秀学术带头人计划(19XD1420700)。
关键词
癌
肝细胞
遗传异质性
药物筛选试验
抗肿瘤
治疗学
Carcinoma,Hepatocellular
Genetic Heterogeneity
Drug Screening Assays,Antitumor
Therapeutics
